Skip to content

Bioalmanac

Eloralintide

LY3841136

Clinical trials

Status reviewed 18 Aug 2026

An amylin receptor agonist that produced up to 20% weight loss in phase 2, as a single agent. That last part is what makes it notable.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Do not freeze once mixed.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Reconstitution — 5 mg vial, 3000 mcg dose

On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.

Water addedConcentrationVolume to drawUnitsDoses per vial
1 mL5 mg/mL0.6 mL60 units1.7
2 mL2.5 mg/mLExceeds a 1 mL barrel
3 mL1.667 mg/mLExceeds a 1 mL barrel
5 mL1 mg/mLExceeds a 1 mL barrel

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Phase 2 dose range1000–3000 mcgOnce weekly, reached by escalationClinical trial

When to stop

  • Vomiting severe enough that you cannot keep fluids down.
  • Losing weight faster than roughly 1% of body weight per week, or being unable to eat adequately.
  • Severe, persistent abdominal pain.
  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.

Not approved anywhere. Phase 2 is complete and phase 3 began in late 2025. Anything sold as eloralintide is a research chemical produced outside the controls a future approval would rest on.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/eloralintide

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.